Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
- PMID: 15214887
- PMCID: PMC7129386
- DOI: 10.1111/j.1469-0691.2004.00956.x
Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
Abstract
Treatment of severe acute respiratory syndrome (SARS) is experimental, and the effectiveness of ribavirin-steroid therapy is unclear. Forty SARS patients with progressive disease after ribavirin treatment and 1.5 g of pulsed methylprednisolone were given either convalescent plasma (n = 19) or further pulsed methylprednisolone (n = 21) in a retrospective non-randomised study. Good clinical outcome was defined as discharge by day 22 following the onset of symptoms. Convalescent plasma was obtained from recovered patients after informed consent. Patients in the plasma group had a shorter hospital stay (p 0.001) and lower mortality (p 0.049) than the comparator group. No immediate adverse effects were observed following plasma infusion.
References
-
- Lee N, Hui DS, Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986–1994. - PubMed
-
- Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–1966. - PubMed
-
- Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1967–1976. - PubMed
-
- Centers for Disease Control and Prevention. Update: severe acute respiratory syndrome. MMWR 2003; 52: 388–390. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
